ÂÜÀòÂÒÂ×

Pamela L. Esposito, PhD is currently the Chief Business Officer of Replimune (NASDAQ REPL). Since its inception, Pamela has been responsible for both corporate and business development, having raised over $400M. Over the past 18 years, Pamela has held a variety of strategy, commercial and business development positions in small biotech companies, playing lead roles in transformative deals for each company. Previously, she was Chief Business Officer at Ra Pharmaceuticals (NASDAQ RARX). As an early member of Ra’s senior management team, Pamela played a leadership role in strategy, helping Ra transform from a discovery platform to a clinical stage company and raising approximately $58 million in a Series B mezzanine funding round. Prior to Ra, she was VP of Business Development at Biovex and led the negotiation of the acquisition of the company by Amgen. Early in her career, she was a director at Bioduro based in Beijing, China and Vion Pharmaceuticals in New Haven, CT. Currently, Pamela sits on the board of directors of Accent Therapeutics. Pamela earned a PhD in pharmacology from Tufts University School of Medicine and a BA from Dartmouth College.